UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen
•UspA2 is a potential Moraxella catarrhalis (Mcat) vaccine antigen.•UspA2 was shown to be immunogenic and to protect against lung colonization in mice.•UspA2 antibodies generated in three species were able to kill various Mcat strains.•UspA2 antibodies cross-reacted with variant UspA2H and UspA1.•Us...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2021-09, Vol.39 (39), p.5641-5649 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5649 |
|---|---|
| container_issue | 39 |
| container_start_page | 5641 |
| container_title | Vaccine |
| container_volume | 39 |
| creator | Ysebaert, Carine Castado, Cindy Mortier, Marie-Cécile Rioux, Stéphane Feron, Christiane Di Paolo, Emmanuel Weynants, Vincent Blais, Normand Devos, Nathalie Hermand, Philippe |
| description | •UspA2 is a potential Moraxella catarrhalis (Mcat) vaccine antigen.•UspA2 was shown to be immunogenic and to protect against lung colonization in mice.•UspA2 antibodies generated in three species were able to kill various Mcat strains.•UspA2 antibodies cross-reacted with variant UspA2H and UspA1.•UspA2 is a cross-reactive Mcat antigen showing properties of a vaccine candidate.
Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine would help to reduce the morbidity and mortality associated with these diseases. UspA2 is an Mcat surface antigen considered earlier as vaccine candidate before the interest in this molecule vanished due to sequence variability. However, the observation that some conserved domains are the target of bactericidal antibodies prompted us to reconsider UspA2 as a potential vaccine antigen.
We first determined its prevalence among the COPD patients from the AERIS study, as the prevalence of UspA2 in a COPD-restricted population had yet to be documented. The gene was found in all Mcat isolates either as UspA2 or UspA2H variant. The percentage of UspA2H variant was higher than in any report so far, reaching 51%. A potential link between the role of UspA2H in biofilm formation and this high prevalence is discussed.
To study further UspA2 as a vaccine antigen, recombinant UspA2 molecules were designed and used in animal models and bactericidal assays. We showed that UspA2 is immunogenic and that UspA2 immunization clears Mcat pulmonary challenge in a mouse model. In a serum bactericidal assay, anti-UspA2 antibodies generated in mice, guinea pigs or rabbits were able to kill Mcat strains of various origins, including a subset of isolates from the AERIS study, cross-reacting with UspA2H and even UspA1, a closely related Mcat surface protein.
In conclusion, UspA2 is a cross-reactive Mcat antigen presenting the characteristics of a vaccine candidate. |
| doi_str_mv | 10.1016/j.vaccine.2021.08.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2566046063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21010008</els_id><sourcerecordid>2572514090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-84c8bca68e8640826b34b79b0e84396a6f75b7529b97070cdfc73c17b99cbf683</originalsourceid><addsrcrecordid>eNqFkD1PwzAURS0EEqXwE5AisbAkPDuOPyZUVXxJRSxUYrNs1wFHaVLspIJ_j0s7sTB5eOc933sQusRQYMDspim22lrfuYIAwQWIAoAcoQkWvMxJhcUxmgBhNKcY3k7RWYwNAFQllhM0W8bNjGQ-ZjqzoY8x34R-cHbwW5c990F_ubZNIz3oED50m8DDZ5nuBv_uunN0Uus2uovDO0XL-7vX-WO-eHl4ms8WuaWYD7mgVhirmXCCURCEmZIaLg04QUvJNKt5ZXhFpJEcONhVbXlpMTdSWlMzUU7R9f5uCvg5ujiotY92l65z_RgVqRgDyoCVCb36gzb9GLqULlE8GaEgIVHVnvrtHVytNsGvdfhWGNROrGrUoavaiVUgVBKb9m73ey613XoXVLTeddatfEji1Kr3_1z4Af8vgoo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2572514090</pqid></control><display><type>article</type><title>UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Ysebaert, Carine ; Castado, Cindy ; Mortier, Marie-Cécile ; Rioux, Stéphane ; Feron, Christiane ; Di Paolo, Emmanuel ; Weynants, Vincent ; Blais, Normand ; Devos, Nathalie ; Hermand, Philippe</creator><creatorcontrib>Ysebaert, Carine ; Castado, Cindy ; Mortier, Marie-Cécile ; Rioux, Stéphane ; Feron, Christiane ; Di Paolo, Emmanuel ; Weynants, Vincent ; Blais, Normand ; Devos, Nathalie ; Hermand, Philippe</creatorcontrib><description>•UspA2 is a potential Moraxella catarrhalis (Mcat) vaccine antigen.•UspA2 was shown to be immunogenic and to protect against lung colonization in mice.•UspA2 antibodies generated in three species were able to kill various Mcat strains.•UspA2 antibodies cross-reacted with variant UspA2H and UspA1.•UspA2 is a cross-reactive Mcat antigen showing properties of a vaccine candidate.
Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine would help to reduce the morbidity and mortality associated with these diseases. UspA2 is an Mcat surface antigen considered earlier as vaccine candidate before the interest in this molecule vanished due to sequence variability. However, the observation that some conserved domains are the target of bactericidal antibodies prompted us to reconsider UspA2 as a potential vaccine antigen.
We first determined its prevalence among the COPD patients from the AERIS study, as the prevalence of UspA2 in a COPD-restricted population had yet to be documented. The gene was found in all Mcat isolates either as UspA2 or UspA2H variant. The percentage of UspA2H variant was higher than in any report so far, reaching 51%. A potential link between the role of UspA2H in biofilm formation and this high prevalence is discussed.
To study further UspA2 as a vaccine antigen, recombinant UspA2 molecules were designed and used in animal models and bactericidal assays. We showed that UspA2 is immunogenic and that UspA2 immunization clears Mcat pulmonary challenge in a mouse model. In a serum bactericidal assay, anti-UspA2 antibodies generated in mice, guinea pigs or rabbits were able to kill Mcat strains of various origins, including a subset of isolates from the AERIS study, cross-reacting with UspA2H and even UspA1, a closely related Mcat surface protein.
In conclusion, UspA2 is a cross-reactive Mcat antigen presenting the characteristics of a vaccine candidate.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.08.002</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>AERIS ; Amino acids ; Animal models ; Antibodies ; Antigens ; Biofilms ; Chromatography ; Chronic obstructive pulmonary disease ; Conserved sequence ; COPD ; Cross-reactivity ; Guinea pigs ; Immunization ; Immunogenicity ; Laboratories ; Lung diseases ; Moraxella catarrhalis ; Morbidity ; Obstructive lung disease ; Otitis media ; Pathogens ; Pediatrics ; Proteins ; Rabbits ; UspA2 ; Vaccine ; Vaccines</subject><ispartof>Vaccine, 2021-09, Vol.39 (39), p.5641-5649</ispartof><rights>2021 GlaxoSmithKline Biologicals SA</rights><rights>2021. GlaxoSmithKline Biologicals SA</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-84c8bca68e8640826b34b79b0e84396a6f75b7529b97070cdfc73c17b99cbf683</citedby><cites>FETCH-LOGICAL-c417t-84c8bca68e8640826b34b79b0e84396a6f75b7529b97070cdfc73c17b99cbf683</cites><orcidid>0000-0001-6675-8293 ; 0000-0002-6163-4838 ; 0000-0001-7954-6644 ; 0000-0002-4306-9441</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2572514090?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids></links><search><creatorcontrib>Ysebaert, Carine</creatorcontrib><creatorcontrib>Castado, Cindy</creatorcontrib><creatorcontrib>Mortier, Marie-Cécile</creatorcontrib><creatorcontrib>Rioux, Stéphane</creatorcontrib><creatorcontrib>Feron, Christiane</creatorcontrib><creatorcontrib>Di Paolo, Emmanuel</creatorcontrib><creatorcontrib>Weynants, Vincent</creatorcontrib><creatorcontrib>Blais, Normand</creatorcontrib><creatorcontrib>Devos, Nathalie</creatorcontrib><creatorcontrib>Hermand, Philippe</creatorcontrib><title>UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen</title><title>Vaccine</title><description>•UspA2 is a potential Moraxella catarrhalis (Mcat) vaccine antigen.•UspA2 was shown to be immunogenic and to protect against lung colonization in mice.•UspA2 antibodies generated in three species were able to kill various Mcat strains.•UspA2 antibodies cross-reacted with variant UspA2H and UspA1.•UspA2 is a cross-reactive Mcat antigen showing properties of a vaccine candidate.
Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine would help to reduce the morbidity and mortality associated with these diseases. UspA2 is an Mcat surface antigen considered earlier as vaccine candidate before the interest in this molecule vanished due to sequence variability. However, the observation that some conserved domains are the target of bactericidal antibodies prompted us to reconsider UspA2 as a potential vaccine antigen.
We first determined its prevalence among the COPD patients from the AERIS study, as the prevalence of UspA2 in a COPD-restricted population had yet to be documented. The gene was found in all Mcat isolates either as UspA2 or UspA2H variant. The percentage of UspA2H variant was higher than in any report so far, reaching 51%. A potential link between the role of UspA2H in biofilm formation and this high prevalence is discussed.
To study further UspA2 as a vaccine antigen, recombinant UspA2 molecules were designed and used in animal models and bactericidal assays. We showed that UspA2 is immunogenic and that UspA2 immunization clears Mcat pulmonary challenge in a mouse model. In a serum bactericidal assay, anti-UspA2 antibodies generated in mice, guinea pigs or rabbits were able to kill Mcat strains of various origins, including a subset of isolates from the AERIS study, cross-reacting with UspA2H and even UspA1, a closely related Mcat surface protein.
In conclusion, UspA2 is a cross-reactive Mcat antigen presenting the characteristics of a vaccine candidate.</description><subject>AERIS</subject><subject>Amino acids</subject><subject>Animal models</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biofilms</subject><subject>Chromatography</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Conserved sequence</subject><subject>COPD</subject><subject>Cross-reactivity</subject><subject>Guinea pigs</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Laboratories</subject><subject>Lung diseases</subject><subject>Moraxella catarrhalis</subject><subject>Morbidity</subject><subject>Obstructive lung disease</subject><subject>Otitis media</subject><subject>Pathogens</subject><subject>Pediatrics</subject><subject>Proteins</subject><subject>Rabbits</subject><subject>UspA2</subject><subject>Vaccine</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkD1PwzAURS0EEqXwE5AisbAkPDuOPyZUVXxJRSxUYrNs1wFHaVLspIJ_j0s7sTB5eOc933sQusRQYMDspim22lrfuYIAwQWIAoAcoQkWvMxJhcUxmgBhNKcY3k7RWYwNAFQllhM0W8bNjGQ-ZjqzoY8x34R-cHbwW5c990F_ubZNIz3oED50m8DDZ5nuBv_uunN0Uus2uovDO0XL-7vX-WO-eHl4ms8WuaWYD7mgVhirmXCCURCEmZIaLg04QUvJNKt5ZXhFpJEcONhVbXlpMTdSWlMzUU7R9f5uCvg5ujiotY92l65z_RgVqRgDyoCVCb36gzb9GLqULlE8GaEgIVHVnvrtHVytNsGvdfhWGNROrGrUoavaiVUgVBKb9m73ey613XoXVLTeddatfEji1Kr3_1z4Af8vgoo</recordid><startdate>20210915</startdate><enddate>20210915</enddate><creator>Ysebaert, Carine</creator><creator>Castado, Cindy</creator><creator>Mortier, Marie-Cécile</creator><creator>Rioux, Stéphane</creator><creator>Feron, Christiane</creator><creator>Di Paolo, Emmanuel</creator><creator>Weynants, Vincent</creator><creator>Blais, Normand</creator><creator>Devos, Nathalie</creator><creator>Hermand, Philippe</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6675-8293</orcidid><orcidid>https://orcid.org/0000-0002-6163-4838</orcidid><orcidid>https://orcid.org/0000-0001-7954-6644</orcidid><orcidid>https://orcid.org/0000-0002-4306-9441</orcidid></search><sort><creationdate>20210915</creationdate><title>UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen</title><author>Ysebaert, Carine ; Castado, Cindy ; Mortier, Marie-Cécile ; Rioux, Stéphane ; Feron, Christiane ; Di Paolo, Emmanuel ; Weynants, Vincent ; Blais, Normand ; Devos, Nathalie ; Hermand, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-84c8bca68e8640826b34b79b0e84396a6f75b7529b97070cdfc73c17b99cbf683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>AERIS</topic><topic>Amino acids</topic><topic>Animal models</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biofilms</topic><topic>Chromatography</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Conserved sequence</topic><topic>COPD</topic><topic>Cross-reactivity</topic><topic>Guinea pigs</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Laboratories</topic><topic>Lung diseases</topic><topic>Moraxella catarrhalis</topic><topic>Morbidity</topic><topic>Obstructive lung disease</topic><topic>Otitis media</topic><topic>Pathogens</topic><topic>Pediatrics</topic><topic>Proteins</topic><topic>Rabbits</topic><topic>UspA2</topic><topic>Vaccine</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ysebaert, Carine</creatorcontrib><creatorcontrib>Castado, Cindy</creatorcontrib><creatorcontrib>Mortier, Marie-Cécile</creatorcontrib><creatorcontrib>Rioux, Stéphane</creatorcontrib><creatorcontrib>Feron, Christiane</creatorcontrib><creatorcontrib>Di Paolo, Emmanuel</creatorcontrib><creatorcontrib>Weynants, Vincent</creatorcontrib><creatorcontrib>Blais, Normand</creatorcontrib><creatorcontrib>Devos, Nathalie</creatorcontrib><creatorcontrib>Hermand, Philippe</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ysebaert, Carine</au><au>Castado, Cindy</au><au>Mortier, Marie-Cécile</au><au>Rioux, Stéphane</au><au>Feron, Christiane</au><au>Di Paolo, Emmanuel</au><au>Weynants, Vincent</au><au>Blais, Normand</au><au>Devos, Nathalie</au><au>Hermand, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen</atitle><jtitle>Vaccine</jtitle><date>2021-09-15</date><risdate>2021</risdate><volume>39</volume><issue>39</issue><spage>5641</spage><epage>5649</epage><pages>5641-5649</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•UspA2 is a potential Moraxella catarrhalis (Mcat) vaccine antigen.•UspA2 was shown to be immunogenic and to protect against lung colonization in mice.•UspA2 antibodies generated in three species were able to kill various Mcat strains.•UspA2 antibodies cross-reacted with variant UspA2H and UspA1.•UspA2 is a cross-reactive Mcat antigen showing properties of a vaccine candidate.
Moraxella catarrhalis (Mcat) is a key pathogen associated with exacerbations of chronic obstructive pulmonary disease (COPD) in adults and playing a significant role in otitis media in children. A vaccine would help to reduce the morbidity and mortality associated with these diseases. UspA2 is an Mcat surface antigen considered earlier as vaccine candidate before the interest in this molecule vanished due to sequence variability. However, the observation that some conserved domains are the target of bactericidal antibodies prompted us to reconsider UspA2 as a potential vaccine antigen.
We first determined its prevalence among the COPD patients from the AERIS study, as the prevalence of UspA2 in a COPD-restricted population had yet to be documented. The gene was found in all Mcat isolates either as UspA2 or UspA2H variant. The percentage of UspA2H variant was higher than in any report so far, reaching 51%. A potential link between the role of UspA2H in biofilm formation and this high prevalence is discussed.
To study further UspA2 as a vaccine antigen, recombinant UspA2 molecules were designed and used in animal models and bactericidal assays. We showed that UspA2 is immunogenic and that UspA2 immunization clears Mcat pulmonary challenge in a mouse model. In a serum bactericidal assay, anti-UspA2 antibodies generated in mice, guinea pigs or rabbits were able to kill Mcat strains of various origins, including a subset of isolates from the AERIS study, cross-reacting with UspA2H and even UspA1, a closely related Mcat surface protein.
In conclusion, UspA2 is a cross-reactive Mcat antigen presenting the characteristics of a vaccine candidate.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.vaccine.2021.08.002</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6675-8293</orcidid><orcidid>https://orcid.org/0000-0002-6163-4838</orcidid><orcidid>https://orcid.org/0000-0001-7954-6644</orcidid><orcidid>https://orcid.org/0000-0002-4306-9441</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2021-09, Vol.39 (39), p.5641-5649 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2566046063 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | AERIS Amino acids Animal models Antibodies Antigens Biofilms Chromatography Chronic obstructive pulmonary disease Conserved sequence COPD Cross-reactivity Guinea pigs Immunization Immunogenicity Laboratories Lung diseases Moraxella catarrhalis Morbidity Obstructive lung disease Otitis media Pathogens Pediatrics Proteins Rabbits UspA2 Vaccine Vaccines |
| title | UspA2 is a cross-protective Moraxella catarrhalis vaccine antigen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A37%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=UspA2%20is%20a%20cross-protective%20Moraxella%20catarrhalis%20vaccine%20antigen&rft.jtitle=Vaccine&rft.au=Ysebaert,%20Carine&rft.date=2021-09-15&rft.volume=39&rft.issue=39&rft.spage=5641&rft.epage=5649&rft.pages=5641-5649&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.08.002&rft_dat=%3Cproquest_cross%3E2572514090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2572514090&rft_id=info:pmid/&rft_els_id=S0264410X21010008&rfr_iscdi=true |